Smart Carrier
Platform

FINNCURE’s patented carrier platform uses surface functionalization to direct synthetic particles to specific cellular receptors, enabling targeted therapeutic delivery and receptor-level blocking. A high density of targeting ligands can be displayed on each particle, with up to ~444 ligands per particle demonstrated in our studies, providing more opportunities for receptor binding.

As one application of the platform, FINNCURE develops virus-mimicking particles (VMPs) inspired by the highly specific receptor-recognition mechanisms of viruses, without using viral carrier material.

FINNCURE’s platform can be adapted across therapeutic payloads, receptor targets, carrier materials, and administration routes. It supports payloads ranging from small molecules and biologics to genetic medicines. The platform supports high drug loading capacity, with up to 40% demonstrated.

FINNCURE has extensive experience with ACE2 as a proof-of-concept receptor, while the platform is being expanded to additional receptor targets.

FINNCURE’s surface engineering can be used for more than carrying therapeutic payloads. Depending on the targeting design, particles can be engineered to perform different biological functions, including receptor blocking and immune stimulation.

In preclinical studies, functionalized VMPs have achieved 70–76% inhibition of pseudoviral cell entry, compared with approximately 40% inhibition with non-functionalized nanoparticles.

FINNCURE’s surface functionalization promotes receptor-mediated uptake in intended target cells while reducing reliance on non-specific passive diffusion across cell membranes. In preclinical studies, functionalized particles have demonstrated enhanced uptake in target cells within approximately 30–60 minutes, depending on cell type.

FINNCURE has established expertise in intranasal and pulmonary delivery. Preclinical studies have demonstrated targeted lung localization, prolonged pulmonary retention, and minimal distribution to non-target organs following inhaled administration.

In repeated-dose preclinical studies, the particles demonstrated favorable tolerability with no acute toxicity, no significant inflammation in target tissue, and no changes in animal behavior or body weight.

FINNCURE’s proprietary manufacturing technology enables precise control over particle characteristics. PDI values as low as 0.13 demonstrate a narrow and uniform particle size distribution. In addition, the production of several grams in a single manufacturing unit demonstrates the potential for scalability.

FINNCURE's technology creates IP opportunities for both new and existing therapeutic compounds. It can strengthen patent protection for new therapies while enabling lifecycle extension and additional patent opportunities for compounds approaching patent expiry.

The technology has been evaluated through independent in vitro studies, preclinical research, and peer-reviewed publications, including studies published in Nano Letters.

FINNCURE is currently preparing its first-in-human study with Evidenze, a leading clinical research organization.